TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Myeloma Patient Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must sign, and/or their legally acceptable representative where applicable must sign, a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements~* Have a diagnosis of relapsed MM \[according to 2014 International Myeloma Working Group (IMWG) criteria\] with 1 to 3 prior lines of therapy. (An induction regimen followed by autologous stem cell transplantation and single-agent maintenance therapy will be considered a single line of therapy.)~* Participants must have initiated a new line of induction therapy that includes a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) within 90 days prior to enrollment. A short course of corticosteroids is allowed prior to initiating the new line of induction therapy~* Must be willing and able to complete the protocol-required patient-reported outcome (PROs)~Exclusion Criteria:~* Participant has plasma cell leukemia \[greater than (\>) 2.0 \* 10\^9 per liter\] circulating plasma cells by standard differential), Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and/or skin changes), or amyloid light-chain amyloidosis~* Participant has a life expectancy of less than 6 months~* At the time of screening, participant is enrolled in an interventional clinical trial for MM using an anti-neoplastic agent that is not currently approved by the United States (US) Food and Drug Administration (FDA)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Relapsed Multiple Myeloma Participants (Type: None): The participants in the United States with a confirmed diagnosis of relapsed multiple myeloma following 1 to 3 prior lines of therapy who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments as per routine clinical practice within 90 days prior to study enrollment. These participants will be observed for the sequence of systemic myeloma treatments used during routine clinical practice, considering the life expectancy of patients with myeloma in the registry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Molekule for Allergic Rhinitis/Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic allergic rhinitis and/or conjunctivitis by history~2. History of adult asthma requiring medications now or in the past~3. Age ≥18~4. CARAT score less than 24~Exclusion Criteria:~1. Participant is \<18 years-old~2. Use of systemic corticosteroids within 14 days of study initiation~3. Treatment with biologic agents or allergen immunotherapy~4. Treatment with other immunomodulators (cyclosporine, azathioprine, hydroxychloroquine, etc)~5. Sensitive to fan sound or blue/purple light at night time

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Active air purifier arm (Type: EXPERIMENTAL): Active portable air purifier for 1 month at bedside
- Sham air purifier arm (Type: SHAM_COMPARATOR): Placebo portable air purifier for 1 month at bedside

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or Older~* Mild-to-moderate primary open angle glaucoma and visually significant cataract with plans to undergo clear cornea cataract surgery with Phacoemulsification and implantation of posterior chamber IOL combined with minimally invasive glaucoma surgery ( MIGS) procedure in both eyes.~Exclusion Criteria:~* Use of Topical steroid, systemic steroid or intravitreal steroid implants within last 3 months~* Previous Corneal surgery or pathology~* Active or history of chronic or recurrent inflammatory eye disease in either eye~* Ocular Pain in either eye~* Proliferative diabetic retinopathy in either eye~* Significant macular pathology detected on macular optical coherence tomography evaluation at the screening visit in either eye.~* Laser or incisional ocular surgery during the study period and 6 months prior in either eye~* Systemic concomitant pain medication management with the pharmacology class of Oxycodone~* Systemic NSAIDS use \>/=750 mg daily~* Clinically significant macular edema~* History of cystoid macular edema in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Dextenza 0.4mg (Type: EXPERIMENTAL): Intracanalicular insert
- Durezol 0.05% (Type: ACTIVE_COMPARATOR): difluprednate ophthalmic emulsion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating a Novel Web-based Intervention for Breast Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Eligible are women who~* had breast cancer diagnosed less than 4 years ago, classified as T0-4, N0-1, M0~* completed acute treatment for breast cancer at least 6 month ago. This applies for surgery, chemotherapy or radiation, whichever occurred last. (Prophylactic treatment with anti-hormones like tamoxifen, aromatase-inhibitors or bisphosphonates is allowed).~* are competent in German language~* provide written consent to study procedures~* are willing to provide the discharge letter from oncology (to verify diagnosis and therapies)~Exclusion Criteria:~Women are not eligible if they~* have a prior history of breast cancer (other than the current one) or any other cancer except basal or squamous cell skin cancer~* suffer from the following autoimmune and/or inflammatory diseases: rheumatoid arthritis, lupus erythematodes, psoriasis, multiple sclerosis or inflammatory breast cancer~* have a history of schizophrenia, bipolar disorder, or an established diagnosis of borderline personality disorder~* have elevated current suicide risk~* routinely attend psychotherapy, either 1:1, group-therapy or web-based interaction (at least two sessions per month)~* practice 5 hours or more of vigorous physical activity per week (e.g. training for marathon)~* have cognitive impairment~* abuse alcohol or drugs

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Optimune (Type: EXPERIMENTAL): Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
- Care-as-Usual (Type: ACTIVE_COMPARATOR): As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Clinical diagnosis of Sepsis~* Mechanical ventilation due to acute pulmonary dysfunction~* One additional (second) acute sepsis-related organ dysfunction~Exclusion Criteria~* Pregnant women and nursing mothers~* Conditions or medications associated with an increased risk of bleeding/complications from anticoagulation~* Previous episode of sepsis during this hospitalization~* PaO2/FiO2 ratio \< 300~* Severe granulocytopenia (leukocytes \<500 / μl)~* Acute hepatic diseases or severe liver failure or cirrhosis~* Chronic cardiovascular disease precluding extracorporeal treatment~* Human immunodeficiency virus complicated by AIDS defining illness~* Evidence of active bleeding - uncontrolled hemorrhage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): S.A.F.E.BT plus Standard of Care therapy
- Group B (Type: NO_INTERVENTION): Standard of Care therapy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-proven diagnosis of prostate adenocarcinoma, diagnosed within 1 year of randomization~* Either NCCN-defined low-risk disease (T1c-T2a, Gleason score 3+3=6, PSA \<10), intermediate-risk disease (Gleason score 3+4=7, 4+3=7, T2b-c and/or PSA 10-20; ) or high-risk disease due to Gleason score 8-10 and/or PSA \>20 ng/ml, but not due to T3-T4 disease on physical exam.~Exclusion Criteria:~* History of prior pelvic radiation (external beam or brachytherapy)~* Prior or concurrent lymphomatous/hematogenous malignancy, or history of prior/concurrent invasive malignancy during the past 5 years~* Very high risk prostate cancer (T3b-T4 on clinical exam, Primary Gleason pattern 5, or \>4 cores with Gleason score 8-10)~* History of prior chemotherapy for prostate cancer~* History of irritable bowel disease~* Evidence of lymph node involvement~* AUA score \>15~* Prostate size \> 90 cc

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Endorectal balloon - Radiation therapy (Type: EXPERIMENTAL): Group 1 : Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
- Rectal spacer - Radiation therapy (Type: EXPERIMENTAL): Group 2 : Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: OPSCC N0 Nodal Control With Reduced IMRT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patient must be clinically referred for radiation for stage I-IVb OPSCCA~* tumor must be HPV-associated p16+~* patient must be able to lie flat and tolerate immobilization systems~Exclusion Criteria:~* patients may not be receiving any investigational agents~* prior radiation to head and neck~* any other malignancy except non-melanomatous skin cancer or a carcinoma not of head and neck origin with patient being disease free for at least 5 years~* any major medical, psychiatric, or neurologic illness~* pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reduced Intensity Radiation (Type: EXPERIMENTAL): 39.6 Gy radiation to clinically uninvolved cervical lymphatics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reamed Locked Plating - Metaphyseal Fractures of the Distal Femur and Tibia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High energy metaphyseal fracture (distal femur or tibia) indicated for plate fixation (open or closed)~* Adult, acute fractures only~Exclusion Criteria:~* Unable to ream fractured bone~* Subject is unable, unwilling or unlikely to follow up~* Subject is under age 18 years~* Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- RIA bone graft (Type: ACTIVE_COMPARATOR): Surgery: open reduction and internal fixation (ORIF) of high energy metaphyseal fractures with Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
- Surgery without bone graft (Type: ACTIVE_COMPARATOR): Surgery:open reduction and internal fixation (ORIF) of high energy metaphyseal fractures without Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* Subjects must have documented newly diagnosed symptomatic multiple myeloma requiring front-line treatment.~* Patients should be considered transplant-eligible~* Subjects will receive front-line induction therapy with a triplet regimen consisting of bortezomib, thalidomide and dexamethasone (VTD).~* To enter to the study at the same time of start anti myeloma induction therapy.~* Ages eligible for study: 18 to 70 years.~* Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.~Exclusion Criteria:~* Patients with the diagnosis of plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome or amyloidosis of light chain.~* Patients with smouldering multiple myeloma or monoclonal gammopathy of undeterminated significance.~* Patients considered non-transplant-eligible.~* Grade ≥2 of peripheral neuropathy.~* Prior history of documented any venous thromboembolism and arterial thrombosis event~* Active or high risk of bleeding.~* Need for on-going anticoagulant or antiplatelet treatment.~* Contraindication of anticoagulant prophylaxis~* Uncontrolled hypertension: systolic blood pressure \>200 mmHg and/or diastolic blood pressure \>100 mmHg.~* HIV, HBV or HCV-positive active.~* Expected survival \<6 months.~* Weight \<40 Kg.~* Low platelet count (\<50 x109/L).~* ALT \>3x UNL, bilirubin \>2x ULN.~* Creatinine clearance \<30 mL/min.~* Women of childbearing potential who are unwilling to use an acceptable method of contraception.~* Women of childbearing potential who are pregnant or breastfeeding.~* Women with a positive pregnancy test on enrollment, prior to investigational product administration.~* Administration of any investigational drug currently or within 30 days prior to planned enrollment into this study.~* Subjects unwilling or unable to comply with study medication instructions or study procedures (e.g. bilateral lower extremity venous ultrasonography).~* Known allergies to ingredients contained in apixaban.~* Use of any contraindicated medications with apixaban (see section 5.4.1).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Apixaban (single arm) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI at enrollment \>/= 30~* plan for ASA for preeclampsia prevention~Exclusion Criteria:~* BMI \< 30~* already on ASA

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 81 mg daily aspirin dose (Type: NO_INTERVENTION): obese women \>30 BMI at risk for preeclampsia will receive recommended 81mg ASA
- 162mg daily aspirin dose (Type: ACTIVE_COMPARATOR): obese women \>30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: ABT-888 and Temozolomide for Liver Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathological confirmation of HCC or noninvasive criteria following AASLD guidelines~* Measurable or evaluable disease based on RECIST criteria~* Progressive disease on sorafenib or intolerance to sorafenib~* ECOG performance status 0-2~* Child Pugh Class A or B~* Adequate hepatic, bone marrow, and renal function~Exclusion Criteria:~* Prior ABT-888 or other PARP inhibitor treatment~* Anticipation of need for major surgery during the study~* Any of the following within 6 months before enrollment: myocardial infarction, severe/unstable angina, congestive heart failure, or severe pulmonary disease~* Women who are pregnant or lactating~* Women and men of child-bearing potential who are not using a reliable form of contraception~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 and temozolomide~* Concurrent malignancy (i.e. malignancy other than hepatocellular cancer) unless 1) the subject has been curatively treated and disease free for at least 2 years or 2) the cancer was non-melanoma skin cancer or early cervical cancer.~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (excluding active hepatitis B or C) or psychiatric illness/ social situations that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temozolomide and ABT-888 in HCC patients (Type: EXPERIMENTAL): Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (\>18 years of age, American Society of Anesthesiologists (ASA) \> IIII) who are undergoing only elective primary total knee replacement will be included in the study.~Exclusion Criteria:~* patient refusal to be included in the study, contraindications to regional anesthesia, history of allergy to amide local anesthetics, the presence of a progressive neurological deficit, chronic pain diagnoses, the presence of coagulopathy or infection, or pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo - Concentrate (Type: ACTIVE_COMPARATOR): preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Placebo - Concentrate by mouth.~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain
- Dextromethorphan (Type: EXPERIMENTAL): preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Dextromethorphan 60mg tablet~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain, and dextromethorphan 60mg by mouth twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy